|
|
|
|
LEADER |
01000caa a22002652 4500 |
001 |
NLM110003675 |
003 |
DE-627 |
005 |
20250202085039.0 |
007 |
tu |
008 |
231222s2000 xx ||||| 00| ||eng c |
028 |
5 |
2 |
|a pubmed25n0367.xml
|
035 |
|
|
|a (DE-627)NLM110003675
|
035 |
|
|
|a (NLM)11084863
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
100 |
1 |
|
|a Patrone, G
|e verfasserin
|4 aut
|
245 |
1 |
0 |
|a Nuclear run-on assay using biotin labeling, magnetic bead capture and analysis by fluorescence-based RT-PCR
|
264 |
|
1 |
|c 2000
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
500 |
|
|
|a Date Completed 01.03.2001
|
500 |
|
|
|a Date Revised 29.01.2022
|
500 |
|
|
|a published: Print
|
500 |
|
|
|a Citation Status MEDLINE
|
520 |
|
|
|a In this report, we present a fluorescence-based approach to the assessment of cellular gene expression and transcription rates. Nuclear run-on was performed by supplying biotin-16-UTP to nuclei, and labeled transcripts were bound to streptavidin-coated magnetic beads. Total cDNA was then synthesized by means of random hexamer primed reverse transcription of captured molecules. To monitor transcript abundance in cDNA, both from nuclear run-on and total RNA, we propose a semiquantitative PCR approach based on the use of fluorescent primers
|
650 |
|
4 |
|a Journal Article
|
650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
650 |
|
7 |
|a DNA Primers
|2 NLM
|
650 |
|
7 |
|a Drosophila Proteins
|2 NLM
|
650 |
|
7 |
|a Proto-Oncogene Proteins
|2 NLM
|
650 |
|
7 |
|a RNA, Messenger
|2 NLM
|
650 |
|
7 |
|a Tretinoin
|2 NLM
|
650 |
|
7 |
|a 5688UTC01R
|2 NLM
|
650 |
|
7 |
|a Cycloheximide
|2 NLM
|
650 |
|
7 |
|a 98600C0908
|2 NLM
|
650 |
|
7 |
|a Proto-Oncogene Proteins c-ret
|2 NLM
|
650 |
|
7 |
|a EC 2.7.10.1
|2 NLM
|
650 |
|
7 |
|a Receptor Protein-Tyrosine Kinases
|2 NLM
|
650 |
|
7 |
|a EC 2.7.10.1
|2 NLM
|
650 |
|
7 |
|a Ret protein, Drosophila
|2 NLM
|
650 |
|
7 |
|a EC 2.7.10.1
|2 NLM
|
650 |
|
7 |
|a Uridine Triphosphate
|2 NLM
|
650 |
|
7 |
|a UT0S826Z60
|2 NLM
|
700 |
1 |
|
|a Puppo, F
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Cusano, R
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Scaranari, M
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Ceccherini, I
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Puliti, A
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Ravazzolo, R
|e verfasserin
|4 aut
|
773 |
0 |
8 |
|i Enthalten in
|t BioTechniques
|d 1993
|g 29(2000), 5 vom: 01. Nov., Seite 1012-4, 1016-7
|w (DE-627)NLM012627046
|x 0736-6205
|7 nnns
|
773 |
1 |
8 |
|g volume:29
|g year:2000
|g number:5
|g day:01
|g month:11
|g pages:1012-4, 1016-7
|
912 |
|
|
|a GBV_USEFLAG_A
|
912 |
|
|
|a SYSFLAG_A
|
912 |
|
|
|a GBV_NLM
|
912 |
|
|
|a GBV_ILN_21
|
912 |
|
|
|a GBV_ILN_22
|
912 |
|
|
|a GBV_ILN_39
|
912 |
|
|
|a GBV_ILN_40
|
912 |
|
|
|a GBV_ILN_50
|
912 |
|
|
|a GBV_ILN_60
|
912 |
|
|
|a GBV_ILN_62
|
912 |
|
|
|a GBV_ILN_65
|
912 |
|
|
|a GBV_ILN_70
|
912 |
|
|
|a GBV_ILN_99
|
912 |
|
|
|a GBV_ILN_121
|
912 |
|
|
|a GBV_ILN_130
|
912 |
|
|
|a GBV_ILN_227
|
912 |
|
|
|a GBV_ILN_350
|
912 |
|
|
|a GBV_ILN_618
|
912 |
|
|
|a GBV_ILN_640
|
912 |
|
|
|a GBV_ILN_754
|
912 |
|
|
|a GBV_ILN_2001
|
912 |
|
|
|a GBV_ILN_2002
|
912 |
|
|
|a GBV_ILN_2003
|
912 |
|
|
|a GBV_ILN_2005
|
912 |
|
|
|a GBV_ILN_2006
|
912 |
|
|
|a GBV_ILN_2007
|
912 |
|
|
|a GBV_ILN_2008
|
912 |
|
|
|a GBV_ILN_2009
|
912 |
|
|
|a GBV_ILN_2010
|
912 |
|
|
|a GBV_ILN_2012
|
912 |
|
|
|a GBV_ILN_2015
|
912 |
|
|
|a GBV_ILN_2018
|
912 |
|
|
|a GBV_ILN_2023
|
912 |
|
|
|a GBV_ILN_2035
|
912 |
|
|
|a GBV_ILN_2040
|
912 |
|
|
|a GBV_ILN_2060
|
912 |
|
|
|a GBV_ILN_2099
|
912 |
|
|
|a GBV_ILN_2105
|
912 |
|
|
|a GBV_ILN_2121
|
912 |
|
|
|a GBV_ILN_2470
|
951 |
|
|
|a AR
|
952 |
|
|
|d 29
|j 2000
|e 5
|b 01
|c 11
|h 1012-4, 1016-7
|